Oral allosteric TYK2 inhibitor
Deucravacitinib
Brand names: Sotyktu
Adult dose
Dose: 6mg PO OD
Route: Oral
Frequency: OD
Clinical pearls
- NICE TA907: moderate–severe plaque psoriasis when phototherapy/ciclosporin/methotrexate inadequate
- BAD psoriasis guidance — newer biologic-comparable oral option
- Specialist dermatology with TB / HBV / HCV screening pre-treatment
Contraindications
- Active serious infection
- Active TB
- Severe hepatic impairment
- Pregnancy
- Hypersensitivity
Side effects
- URTI
- Herpes simplex
- Acne
- Folliculitis
- Increased CK
- Hepatotoxicity
- Mood disorders (rare)
Interactions
- Live vaccines
- Other immunosuppressives
Monitoring
- FBC
- LFTs
- CK
- Lipids
- Infection signs
- TB screen at baseline
Reference: BNF; NICE TA907; BAD psoriasis; SmPC; https://bnf.nice.org.uk/drugs/deucravacitinib/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- DOAC Score for Selecting Direct Oral Anticoagulant in Non-Valvular AF · Anticoagulation
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD